Frontiers in Oncology,
Journal Year:
2021,
Volume and Issue:
11
Published: Oct. 18, 2021
In
the
era
of
precision
medicine,
radiation
medicine
is
currently
focused
on
precise
delivery
highly
conformal
treatments.
However,
tremendous
developments
in
targeted
therapy
are
yet
to
fulfill
their
full
promise
and
arguably
have
potential
dramatically
enhance
therapeutic
ratio.
The
increased
ability
molecularly
profile
tumors
both
at
diagnosis
relapse
co-incident
progress
field
radiogenomics
could
potentially
pave
way
for
a
more
personalized
approach
treatment
contrast
current
‘‘one
size
fits
all’’
paradigm.
Few
clinical
trials
date
shown
an
improved
outcome
when
combining
agents
with
therapy,
however,
most
failed
show
benefit,
which
due
limited
preclinical
data.
Several
key
molecular
pathways
theoretically
effect
rationally
either
by
directly
enhancing
tumor
cell
kill
or
indirectly
through
abscopal
combined
novel
immunotherapies.
timing
also
important
determine
greatly
affect
depending
pathway
being
inhibited.
Endocrine Related Cancer,
Journal Year:
2024,
Volume and Issue:
31(3)
Published: Jan. 4, 2024
Radiotherapy
is
one
of
the
major
options
currently
for
cancer
treatment.
causes
cellular
damage
inducing
cell
death,
which
expected
to
be
selective
tumor
cells.
However,
side
effects
that
alter
surrounding
normal
tissue
are
often
hard
avoided.
When
radiation
involves
hypothalamic–pituitary
axis,
growth
hormone
deficiency
(GHD)
frequently
induced,
causing
developmental
and
metabolic-related
diseases
in
childhood
survivors.
Growth
(GH)
replacement
therapy
has
been
used
these
patients
shown
safe
general.
there
some
debating
its
long-term
safety
due
known
roles
GH
growth,
could
related
recurrence.
In
addition,
studies
have
involved
development
resistance
chemotherapy
radiotherapy
through
various
mechanisms.
this
review,
we
will
first
discuss
GHD
induced
after
Then,
role
GH–IGF-1
axis
radioresistance
via
a
mechanism
improving
DNA
repair.
Genetics,
Journal Year:
2024,
Volume and Issue:
227(4)
Published: July 4, 2024
Radiotherapy
is
a
key
treatment
option
for
wide
variety
of
human
tumors,
employed
either
alone
or
alongside
with
other
therapeutic
interventions.
uses
high-energy
particles
to
destroy
tumor
cells,
blocking
their
ability
divide
and
proliferate.
The
effectiveness
radiotherapy
due
genetic
epigenetic
factors
that
determine
how
cells
respond
ionizing
radiation.
These
contribute
the
establishment
resistance
radiotherapy,
which
increases
risk
poor
clinical
prognosis
patients.
Although
mechanisms
by
induce
radioresistance
are
unclear,
evidence
points
out
several
contributing
including
overexpression
DNA
repair
systems,
increased
levels
reactive
oxygen
species,
alterations
in
microenvironment,
enrichment
cancer
stem
cell
populations.
In
this
context,
dysregulation
microRNAs
miRNAs,
critical
regulators
gene
expression,
may
influence
tumors
There
increasing
miRNAs
act
as
sensitizers
enhancers
radioresistance,
regulating
processes
such
damage
response
death
signaling
pathway.
Furthermore,
expression
activity
have
shown
informative
value
overcoming
long-term
radiotoxicity,
revealing
potential
biomarkers.
review,
we
will
discuss
molecular
associated
highlight
central
role
responsible
cellular
radioresistance.
We
also
review
radio-miRs,
radiotherapy-related
hold
promise
biomarkers
pharmacological
targets
sensitize
radioresistant
cells.
Journal of Neuro-Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 16, 2025
The
receptor
tyrosine
kinase
(RTK)/Ras/Raf/MEK/ERK
signaling
pathway
is
one
of
the
most
tumorigenic
pathways
in
cancer,
with
its
hyperactivation
strongly
linked
to
aggressive
nature
glioblastoma
(GBM).
Although
extensive
research
has
focused
on
developing
therapeutics
targeting
this
pathway,
clinical
success
remains
elusive
due
emergence
resistance
mechanisms.
This
review
investigates
how
inhibition
RTK/Ras/Raf/MEK/ERK
alters
transcription
factors,
contributing
acquired
mechanisms
GBM.
It
also
highlights
critical
role
factor
dysregulation
therapeutic
resistance.
Findings
from
key
studies
GBM
were
synthesized
explore
targeted
therapies,
radiation,
and
chemotherapy.
that
factors
undergo
significant
following
inhibition,
Transcription
are
promising
targets
for
overcoming
treatment
GBM,
cotreatment
strategies
combining
inhibitors
factor-targeted
therapies
presenting
a
novel
approach.
Despite
challenges
complex
structures
interactions,
advancements
drug
development
precision
technologies
hold
great
potential.
Continued
essential
refine
these
improve
outcomes
other
cancers.
Frontiers in Oncology,
Journal Year:
2021,
Volume and Issue:
11
Published: Oct. 18, 2021
In
the
era
of
precision
medicine,
radiation
medicine
is
currently
focused
on
precise
delivery
highly
conformal
treatments.
However,
tremendous
developments
in
targeted
therapy
are
yet
to
fulfill
their
full
promise
and
arguably
have
potential
dramatically
enhance
therapeutic
ratio.
The
increased
ability
molecularly
profile
tumors
both
at
diagnosis
relapse
co-incident
progress
field
radiogenomics
could
potentially
pave
way
for
a
more
personalized
approach
treatment
contrast
current
‘‘one
size
fits
all’’
paradigm.
Few
clinical
trials
date
shown
an
improved
outcome
when
combining
agents
with
therapy,
however,
most
failed
show
benefit,
which
due
limited
preclinical
data.
Several
key
molecular
pathways
theoretically
effect
rationally
either
by
directly
enhancing
tumor
cell
kill
or
indirectly
through
abscopal
combined
novel
immunotherapies.
timing
also
important
determine
greatly
affect
depending
pathway
being
inhibited.
